1. The Debate
Single-use vs stainless steel bioreactors splits on scale and batch frequency: single-use (SUB) is the cheaper choice below 2,000 L working volume and under 20 batches per year, delivering a $50–100M facility against $200–500M for a 4 × 10,000 L stainless plant, while stainless steel wins decisively above 5,000 L and 30+ batches per year because whole-process consumables run $40–80k per 2,000 L batch (BioPhorum BPOG 2024) and scale almost linearly. This article maps the CapEx, batch-cost deltas, break-even point and product-specific picks for CHO mAb, biosimilar, gene therapy and multi-product CDMO manufacturers so you can decide which technology fits your facility before committing capital.
Updated 2026-10. Includes commissioning timelines (6–12 months single-use vs 18–36 months stainless) and per-batch cost ranges ($40–80k whole-process consumables at 2,000 L) from BioPhorum 2024 single-use benchmark data.
The single-use bioreactor (SUB) market has grown at approximately 25% CAGR over the past decade, driven by clinical-stage companies that need flexibility and speed-to-clinic without massive capital outlays. But stainless steel still dominates at large commercial scale, where high batch volumes and decades-long product lifecycles make the upfront investment worthwhile.
Neither technology is universally superior. The question is: at what scale, batch frequency, and product type does the economics tip from one to the other? This article provides the data and framework to answer that question for your specific situation.
Single-use (SU): Bioreactor with a pre-sterilized, gamma-irradiated polymer bag as the product-contact vessel. Disposed after each batch. Also called "disposable." Major suppliers: Cytiva (Xcellerex), Sartorius (BIOSTAT STR), Thermo Fisher (HyPerforma), Merck (Mobius) — see the Sartorius Biostat STR vs Thermo HyPerforma vs Cytiva Xcellerex vendor comparison for a side-by-side of the top three platforms.
Stainless steel (SS): Traditional fixed vessels constructed from 316L stainless steel, cleaned in place (CIP) and sterilized in place (SIP) between batches. Reused for thousands of cycles.
2. Capital Cost Comparison
The capital cost advantage of single-use is dramatic. A single-use facility requires no CIP/SIP systems, minimal piping, simplified HVAC (no steam generation), and reduced cleanroom classification in many areas. The savings compound throughout the facility:
The facility timeline is equally different. A single-use facility can be designed, built, and validated in 18–24 months. A stainless steel facility typically requires 36–60 months. For a company racing to supply a newly approved product, this time difference can be worth more than the capital savings.
These are facility-level costs, not bioreactor-level costs. A single 2,000 L SUB vessel costs $200–400K, while a 10,000 L SS vessel costs $500K–$1.5M. The real cost difference is in the infrastructure required to support the vessels. Single-use dramatically simplifies the facility.
3. Operating Cost Comparison
While single-use wins on capital, stainless steel often wins on operating cost per batch—especially at high batch frequencies. The key tradeoff is consumables vs. utilities.
Single-Use Operating Costs
- Biocontainer (bag): $2,000–5,000 per 2,000 L bag
- Tubing, connectors, sensors and pump chambers: $1,000–3,000 per batch
- Filters (0.2 μm, depth): $1,500–4,000 per batch
- Sampling assemblies: $500–1,500 per batch
- Total consumables: $5,000–15,000 per batch
At 100 batches per year, consumables alone cost $500K–$1.5M annually. This cost scales linearly with batch number—no economies of scale.
Stainless Steel Operating Costs
- CIP chemicals (NaOH, acid, sanitizer): $200–500 per cycle
- Water for Injection (WFI): 5,000–10,000 L per CIP cycle at $0.50–$2.00/L
- Steam for SIP: $100–300 per cycle
- Labor (CIP/SIP validation, monitoring): $500–1,500 per cycle
- Total per CIP/SIP cycle: $3,000–8,000
But stainless steel also requires ongoing maintenance: gasket replacement, valve servicing, re-passivation, and periodic requalification. These add $50K–200K per vessel per year in fixed costs regardless of batch frequency.
Labor Comparison
Single-use requires fewer operators because there is no CIP/SIP to run, monitor, and validate. A typical CIP/SIP cycle takes 8–24 hours of vessel time and 2–4 hours of operator attention. With single-use, turnaround between batches can be as short as 4–8 hours (bag change, line setup, leak test). This translates to higher facility utilization and fewer FTEs.
4. The Crossover Point
The crossover point—where the total cost of ownership (capital + operating) is equal for single-use and stainless steel—depends on two primary variables: scale and batch frequency.
Scale crossover: ~2,000–5,000 L working volume
Frequency crossover: ~100–200 batches/year
Below both thresholds: single-use is cheaper
Above both thresholds: stainless steel is cheaper per batch
Mixed (small scale + high frequency, or large scale + low frequency): case-by-case
The scale crossover exists because single-use bags above 2,000 L become increasingly expensive and have engineering limitations (mixing, heat transfer, kLa). The largest commercially available SUBs are currently 4,000–6,000 L, compared to stainless steel vessels that routinely reach 25,000 L or more.
The frequency crossover exists because single-use consumables are a per-batch cost with no amortization. After enough batches, the cumulative consumables cost exceeds the capital savings. At 200+ batches per year with a 5-year facility amortization, stainless steel almost always wins on total cost.
The COVID-19 pandemic exposed a critical vulnerability of single-use: supply chain dependence. When multiple vaccine manufacturers simultaneously ramped up SU demand in 2021–2022, lead times for biocontainers extended from 4–6 weeks to 6–12 months. Stainless steel vessels, once installed, have no such supply chain risk. Factor this into your risk assessment.
Live break-even simulator
The crossover above is a rule of thumb. This runs it for your numbers. Set the annual demand and titer, and the model sizes each technology independently to meet it — batch size sets how many batches you need, turnaround sets how many trains. Then the two cumulative-cost curves race across 20 years and the crossover marks the year stainless steel overtakes. Drag the dashed HORIZON line on the chart (or use the slider) to change the campaign length. Every control updates the numbers as you move it; Run just replays the race from year zero.
Assumptions, all held constant: 70% downstream recovery, 14-day fed-batch culture, 330 operating days per train per year, turnaround 4–8 h single-use vs 8–24 h CIP/SIP stainless, media plus feed at $10.40 per litre of working volume, a 3-year launch ramp to full demand, and no discounting (nominal cash cost). Capital is anchored on the two facility estimates in section 2 — the model returns exactly $75M for 4 × 2,000 L single-use and $350M for 4 × 10,000 L stainless — and scaled from there with a six-tenths rule. The consumables slider is the assumption that moves the answer most, which is why it is a slider rather than a constant. It defaults to $60k per batch, the midpoint of the $40–80k per-batch figure the FAQ below quotes for a full single-use process. Section 3's $5–15k counts the bioreactor train only (bag, tubing, sensors, filters, sampling); it excludes the single-use assemblies used downstream through harvest, chromatography and fill, which is where the rest of the money goes. Slide it down to $15k to compare bioreactors alone rather than facilities. Directional planning tool, not a quotation.
5. Head-to-Head Comparison
| Factor | Single-Use | Stainless Steel |
|---|---|---|
| Capital cost | Low ($50–100M facility) | High ($200–500M facility) |
| Turnaround time | Fast (4–8h, no CIP/SIP) | Slow (8–24h CIP/SIP) |
| Contamination risk | Lower (pre-sterilized) | Higher (cleaning validation required) |
| Maximum scale | ~4,000–6,000 L | Unlimited (>25,000 L) |
| Flexibility | High (multi-product) | Low (often dedicated) |
| Environmental impact | Plastic waste (50–100 kg/batch) | Water/chemical waste (5,000–10,000 L/CIP) |
| Leachables & extractables | Concern (E&L studies required) | Not an issue |
| kLa performance | Lower (30–150 h−1) | Higher (100–400 h−1) |
| Facility build time | 18–24 months | 36–60 months |
| Supply chain risk | Higher (bag supply dependency) | Lower (once installed) |
6. Product-Specific Considerations
The optimal bioreactor technology depends heavily on what you are manufacturing. Here is guidance by product type:
Monoclonal Antibodies (High Volume)
For established commercial mAbs with annual demand >100 kg, stainless steel at >10,000 L scale is almost always the most cost-effective option. The high batch frequency and long product lifecycle (15–20 years) amortize the capital investment. However, many companies use SU for clinical supply and early commercial launch, then transition to SS as demand becomes clear.
Gene Therapy (Small Batches)
AAV and lentiviral vector manufacturing operates at small scale (200–2,000 L) with relatively few batches per year. Single-use is the dominant choice because capital efficiency matters more than consumables cost, and multi-product flexibility is essential (most gene therapy CMOs make multiple products).
Cell Therapy (Patient-Specific)
Autologous cell therapies (CAR-T) are manufactured in individual patient batches, typically in closed, single-use systems. Stainless steel is impractical for this application. Single-use is not just preferred—it is the only viable approach for patient-specific manufacturing.
Biosimilars (Cost-Driven)
Biosimilar manufacturers compete primarily on cost. For established biosimilar products with proven market demand, stainless steel at large scale provides the lowest COGS. Several large biosimilar manufacturers in Asia operate 10,000–25,000 L stainless steel facilities specifically for cost competitiveness.
Clinical Supply (Flexibility)
During clinical development, the ability to quickly switch between products in the same facility is paramount. A single-use facility can manufacture Product A on Monday and Product B on Wednesday with no cross-contamination risk. This flexibility is nearly impossible with dedicated stainless steel vessels without extensive changeover procedures.
Model Your Production Economics
Compare COGS for single-use and stainless steel scenarios with our Fermentation Economics tool.
Fermentation Economics →7. The Hybrid Approach
The most pragmatic solution for many manufacturers is a hybrid facility that combines single-use upstream with stainless steel downstream. This approach captures the benefits of both technologies where they are strongest.
Why Hybrid Works
- Upstream (bioreactors): SU bags are well-suited because each batch requires a fresh, sterile vessel. The contamination risk reduction alone justifies SU in many cases. Scale limits (2,000–4,000 L) are acceptable when multiple SUBs run in parallel.
- Downstream (chromatography): Chromatography columns and resins are inherently reusable—they are designed for hundreds of cycles. Single-use chromatography is expensive and generates massive waste. SS columns with CIP between cycles are far more economical.
- Filtration: TFF cassettes are typically single-use or limited-use regardless of the upstream technology. Depth filters and 0.2 μm filters are always single-use.
The hybrid model is increasingly the default for new mAb facilities built since 2020. It provides the fast turnaround and contamination safety of SU upstream with the cost efficiency and performance of SS downstream.
8. Environmental Perspective
The environmental debate between single-use and stainless steel is more nuanced than it first appears. Each technology generates a different type of waste. This section is a summary; for the modelled numbers, see our full comparison of the single-use vs stainless environmental impact, which puts the two within 0.2% of each other on carbon at matched scale while single-use wins clearly on water.
Single-Use Waste
- Plastic waste: 50–100 kg per 2,000 L batch (bags, tubing, filters, connectors)
- Primarily polyethylene (PE), ethylene vinyl acetate (EVA), and polycarbonate
- Most SU waste is classified as biohazardous and must be incinerated, not recycled
- At 100 batches/year: 5–10 metric tons of plastic waste annually
Stainless Steel Waste
- Water: 5,000–10,000 L of WFI per CIP cycle, plus rinse water
- Chemicals: NaOH (0.5–1 M), phosphoric acid, peracetic acid
- Steam: Energy for SIP (saturated steam at 121°C for 30+ minutes)
- At 100 batches/year: 500,000–1,000,000 L of contaminated wastewater annually
Lifecycle Analysis
Published lifecycle assessments (LCAs) show mixed results. A widely cited 2012 GE Healthcare (now Cytiva) study found that single-use reduces carbon footprint by 33% and water use by 87% compared to stainless steel at the 2,000 L scale. However, critics note that these studies often exclude the environmental cost of plastic resin production and incineration, and that the comparison is not fair at larger scales where SS is more efficient.
The industry trend is toward recyclable single-use materials and take-back programs (Cytiva's Figurate, Sartorius sustainability initiatives), but these programs are still in early stages and cover only a fraction of SU waste.
If your primary concern is water and energy consumption, single-use is greener. If your primary concern is solid waste and plastic pollution, stainless steel is greener. A comprehensive environmental strategy considers both and selects the approach that minimizes total impact for your specific scale and location.
Frequently Asked Questions
Single use vs stainless steel: which should I choose?
Choose single use below 2,000 L working volume and under 20 batches per year. The $50–100M facility CapEx against $200–500M for a 4 × 10,000 L stainless plant dominates the decision at clinical, gene therapy and biosimilar scale, and single-use eliminates CIP/SIP so turnaround drops from 24–72 h to 2–4 h between batches. Choose stainless above 5,000 L or 30+ batches per year, because single-use consumables run $40–80k per 2,000 L batch (BioPhorum BPOG 2024) and scale almost linearly, so a 10,000–25,000 L stainless train with 20–30 year amortisation delivers a lower cost per gram. Between 2,000 L and 5,000 L the comparison is product-specific: gene therapy, multi-product CDMOs and biosimilars generally pick single-use; high-titer commercial mAbs pick stainless.
Single use versus stainless steel biopharma: how do the economics compare?
Single use versus stainless steel in biopharma trades CapEx for OpEx. A 4 × 2,000 L single-use plant lands at $50–100M against $200–500M for a 4 × 10,000 L stainless plant (around four-fold), and commissioning runs 6–12 months versus 18–36 months because every stainless vessel carries a full cleaning-validation package before GMP release. Operating cost flips the other way: single-use whole-process consumables sit at $40–80k per 2,000 L batch (BioPhorum BPOG 2024) and scale almost linearly with batch count, while a stainless CIP/SIP cycle runs $3,000–8,000 and amortised vessel depreciation stretches 20–30 years. For a 2,000 kg/year CHO mAb at 5 g/L titer the crossover sits near year 7–8, with stainless $30–60M ahead over a 10-year campaign.
Single-use bioreactor cost vs stainless: what is the real delta?
On the capital side, a single 2,000 L SUB vessel costs $200–400K against $500K–$1.5M for a 10,000 L stainless vessel, but the real delta sits in the facility. A 4 × 2,000 L single-use plant lands at $50–100M against $200–500M for a 4 × 10,000 L stainless plant, driven mostly by the WFI generation, CIP and SIP skids, orbital-welded piping and automation that stainless requires. On the operating side, single-use consumables run $5,000–15,000 per batch at small scale and $40–80k per 2,000 L batch at commercial scale (BioPhorum BPOG 2024), while a stainless CIP/SIP cycle runs $3,000–8,000 plus $50–200K per vessel per year in fixed maintenance regardless of batch count. The real delta per gram therefore depends on your batches per year and campaign length, which the live break-even simulator in section 4 runs for your own numbers.
What are the main differences between single-use and stainless steel bioreactors?
Single-use bioreactors use a disposable plastic bag (typically up to 2000 L) that is discarded after one batch. Stainless steel bioreactors are fixed vessels (typically 2000–20,000 L) that are cleaned (CIP) and sterilised (SIP) between batches. Key differences: single-use has lower CapEx but higher per-batch consumables cost, faster turnaround (no CIP/SIP), smaller scale ceiling (~2000 L), needs no cleaning validation, and generates plastic waste. Stainless steel has higher CapEx but lower operating cost at high throughput, reaches larger scales (up to 20,000 L), requires extensive CIP/SIP validation, and is more sustainable over long product life.
At what scale does stainless steel become cheaper than single-use?
The crossover point where stainless steel becomes cheaper than single-use is typically between 2000 and 5000 L, depending on batch frequency and facility utilisation. Below 2000 L and fewer than 20 batches per year, single-use nearly always wins on total cost. Above 5000 L with 30+ batches per year, stainless steel wins decisively. Between 2000 and 5000 L the choice depends on product flexibility needs, regulatory strategy, and CapEx availability. Higher batch frequency pushes the crossover point toward the lower end (2000 L) because consumables cost accumulates faster.
Is single-use cheaper than stainless steel?
Single-use is cheaper than stainless steel for small- to mid-scale biopharma manufacturing (<2000 L) and for facilities running fewer than 20 batches per year. Single-use saves $10–40 million in CapEx for a typical 500–2000 L facility and eliminates CIP/SIP validation. However, at large scale (>5000 L) or high batch count (>30/year), cumulative consumables cost ($20–80k per batch) exceeds the amortised cost of stainless steel. Single-use also avoids facility downtime, making it the go-to choice for multi-product CDMO operations and gene therapy.
Which is better for mAb manufacturing: single-use or stainless steel?
For monoclonal antibody (mAb) manufacturing, the choice depends on demand. Single-use (up to 2000 L) is ideal for clinical and early commercial supply up to roughly 100 kg/year of drug substance. Stainless steel (10,000–20,000 L) is the standard for blockbuster mAbs requiring >500 kg/year. Between these scales, many biopharma companies run hybrid facilities: single-use seed train and inoculum feeding a stainless steel production bioreactor. Biosimilar manufacturers increasingly favour 2000 L single-use with high-titer processes (5–10 g/L) to avoid the CapEx of stainless steel.
What are the disadvantages of single-use bioreactors?
The main disadvantages of single-use bioreactors: (1) scale ceiling at around 2000 L (3000–6000 L available from some vendors), (2) high recurring consumables cost ($20,000–80,000 per batch at 2000 L), (3) supply chain risk (bag shortages have affected multiple manufacturers), (4) extractables and leachables characterisation required for each new film/bag combination, (5) plastic waste and carbon footprint, and (6) reduced scalability compared to stainless steel vessels that can be built at 20,000 L or larger.
Are single-use bioreactors sustainable?
Single-use bioreactors have a lower water and energy footprint per batch than stainless steel because they eliminate CIP and SIP (no steam, no cleaning chemicals, no rinse water). However, they generate significant plastic waste. Recent life-cycle assessments show single-use is more sustainable than stainless steel below roughly 2000 L, particularly for campaigns shorter than 5 years. At larger scale or for long-lived products, stainless steel is more sustainable because the embodied carbon of the vessel is amortised over decades of use.
Single-use vs reusable systems: which is the right comparison for biopharmaceutical production?
The single-use vs reusable systems decision in biopharmaceutical production turns on three quantitative drivers: facility throughput, batch frequency and product life-cycle. Single-use (disposable bag) systems suit ≤2000 L scales with fewer than 20 batches per year and short campaigns, because consumables cost stays below the amortised CapEx of stainless steel. Reusable stainless steel wins above 5000 L or with 30+ batches per year, where its 20–30 year amortisation period dominates. Between 2000 and 5000 L the comparison is product-specific: gene therapy, multi-product CDMOs and biosimilars typically choose single-use; high-titer commercial mAbs choose stainless steel. Facility-fit-for-purpose modelling — not vendor preference — should drive the decision.
What is the cost crossover between single-use and stainless steel bioreactors?
The cost crossover sits at 2000–5000 L for typical CHO mAb processes at 30–50 batches per year. At 1000 L and 20 batches per year, single-use saves $15–25M in CapEx and breaks even on OpEx. At 2000 L and 30 batches per year, the two are within 10% on total cost of goods (TCOG). Above 10,000 L and 50 batches per year, stainless steel saves $30–60M over a 10-year campaign because consumables ($40–80k per batch at 2000 L scales linearly) dominate single-use TCOG. Use the bioprocess economics calculator to model your specific scale, batch frequency, titer and depreciation assumptions before committing.
How do you calculate the break-even point between single-use and stainless steel?
Break-even is the year at which the cumulative cost of a stainless steel facility falls below that of a single-use facility sized for the same annual demand: (stainless CapEx − single-use CapEx) ÷ (single-use annual operating cost − stainless annual operating cost). That closed form assumes full output from day one; a real product ramps over its first few years, which pushes the true break-even slightly later, so read it as a lower bound. The step most comparisons miss is sizing each technology independently. Batch size sets how many batches a year you need (kg per batch = working volume × titer × downstream recovery), and turnaround time sets how many parallel trains. Stainless steel does not win by costing less per batch — it wins by needing far fewer batches, so far fewer bags, filters and flow kits get bought. Run it for your own numbers in the live break-even simulator above.
How many single-use bioreactors do you need to replace one large stainless steel vessel?
Divide the stainless working volume by the single-use working volume, then account for turnaround. One 10,000 L stainless vessel produces roughly five times the drug substance per batch of a 2,000 L single-use bioreactor, and because single-use turnaround is faster (4–8 h versus 8–24 h of CIP/SIP) each single-use train fits about 23 batches a year against 22 for stainless. Replacing one 10,000 L stainless train therefore takes roughly five 2,000 L single-use trains running continuously. At 2,000 kg/year and 5 g/L titer that works out to about 13 single-use trains and 286 batches a year against 3 stainless trains and 57 batches — the point at which consumables dominate and the single-use scale ceiling starts to bite.
What is the difference between single-use and stainless-steel bioreactors in biopharma?
Single-use (SU) bioreactors use a pre-sterilised, gamma-irradiated polymer bag inside a rigid holder and are discarded after one batch; stainless-steel (SS) bioreactors are fixed 316L vessels cleaned-in-place (CIP) and sterilised-in-place (SIP) between batches. Facility CapEx typically differs by around four-fold: a 4 × 2,000 L single-use plant lands at $50–100M against $200–500M for a 4 × 10,000 L stainless plant, driven mostly by the WFI generation, CIP and SIP skids, orbital-welded piping and automation that stainless requires. Commissioning timelines run 6–12 months for a single-use suite against 18–36 months for a stainless train, because every stainless vessel carries a full cleaning-validation package before GMP release. Change-over between batches or products is 2–4 h with single-use (bag swap, line setup, leak and integrity test) and 24–72 h with stainless (CIP, SIP, requalification). The scale ceiling differs too: single-use tops out around 2,000 L in common commercial use, with 3,000–6,000 L available from a few vendors, while stainless scales to 25,000 L. Failure modes split along the same line: single-use carries extractables-and-leachables risk from the bag film and gamma-irradiation residues, stainless carries cleaning-validation gaps where carry-over, biofilm or passivation loss can contaminate the next batch. BioPhorum BPOG 2024 single-use benchmark data put whole-process consumables at $40–80k per 2,000 L batch, which is why operating cost per gram flips in favour of stainless above about 5,000 L and 30+ batches per year.
Is single use cheaper than stainless steel at commercial scale?
At commercial scale the answer depends on where "commercial" sits. Single-use is typically the cheaper option up to 2,000 L working volume and under about 20 batches per year. That is the clinical, gene therapy and biosimilar region, because the $50–100M facility CapEx saving against a stainless plant dominates the comparison. Above 5,000 L and with 30+ batches per year the sum reverses: single-use consumables (bags, tubing, filters, sensor assemblies and downstream flow kits) run $40–80k per 2,000 L batch and scale almost linearly, so a stainless 10,000–25,000 L train with its 20–30 year depreciation delivers a lower cost per gram. For a 2,000 kg per year CHO mAb at 5 g/L titer the live break-even simulator on this page puts the crossover near year 7–8 and stainless $30–60M ahead over a 10-year campaign. Run your own demand, titer and vessel sizes through the simulator before committing capital.
Welche Vorteile bieten Single-Use-Technologien gegenüber Edelstahl in der Bioproduktion?
Single-Use-Systeme machen Reinigung und Sterilisation überflüssig (kein CIP/SIP), verkürzen die Rüstzeit, senken das Kreuzkontaminationsrisiko, reduzieren Investitionskosten sowie den Wasser- und Energieverbrauch und ermöglichen einen schnelleren Aufbau und mehr Flexibilität der Anlage. Edelstahl ist im Vorteil bei sehr großem Maßstab (>2000 L), bei sehr langen Kampagnen, in denen die Verbrauchsmaterialkosten dominieren, und wenn Extractables/Leachables oder Versorgungssicherheit eine Rolle spielen.
Kostenvergleich: Single-Use-Technologien vs. Mehrweglösungen in der Biopharma?
Single-Use verlagert die Ausgaben von Investitionskosten (CapEx) zu Verbrauchsmaterialien (OpEx): geringere Anfangsinvestitionen und keine CIP/SIP-Versorgungssysteme, dafür wiederkehrende Kosten für Beutel und Baugruppen, die mit der Chargenzahl und dem Maßstab steigen. Der Kreuzungspunkt wird durch Titer, Chargenhäufigkeit und Maßstab bestimmt; Single-Use ist meist günstiger für Mehrprodukt-, kleinvolumige oder klinische Anwendungen, während sich Edelstahl bei dedizierter großtechnischer kommerzieller Produktion besser amortisiert.
References
- Langer, E.S. & Rader, R.A. (2023). "Single-Use Technologies in Biopharmaceutical Manufacturing." BioPlan Associates Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, 20th Edition.
- Sinclair, A. & Monge, M. (2010). "Quantitative Economic Evaluation of Single Use Disposables in Bioprocessing." Pharmaceutical Engineering, 30(3), 1–8.
- Rawlings, B. & Pora, H. (2009). "Environmental impact of single-use and reusable bioprocess systems." BioProcess International, 7(2), 18–25.
- Pietrzykowski, M., Flanagan, W., Pizzi, V., et al. (2013). "An Environmental Life Cycle Assessment Comparison of Single-Use and Conventional Process Technology for the Production of Monoclonal Antibodies." Journal of Cleaner Production, 41, 150–162.
← See all bioprocess comparisons
Assessing the environmental side of this decision as well as the cost? See our LCA software comparison for bioprocess.